Erscheint 4 Ausgaben pro Jahr
ISSN Druckformat: 1050-6934
ISSN Online: 1940-4379
Indexed in
Hepatitis B Virus: A Comprehensive Strategy for Eliminating Transmission in the United States
ABSTRAKT
There is a global epidemic of hepatitis B virus (HBV) infections affecting more than 350 million people worldwide. This collective review provides the rationale for a comprehensive strategy to eliminate transmission of HBV in the United States. The virologic characteristics of HBV include three forms of HBV surface antigen (HBsAg), HBV core antigen (HbcAg), as well as a circulating peptide, the HBV e antigen (HBeAg). The year 2002 was the 20th anniversary of the use in the United States of the world's first vaccine against HBV. Our prevention strategy involves making HBV vaccine a part of the routine vaccination schedules for all infants in the United States. Hepatitis B immune globulin (HBIG) is another useful adjunct for prophylaxis that provides temporary protection (i.e., 3-6 months) and is recommended in only certain postexposure settings. The routes for administration of HBV vaccine and HBIG are intramuscular sites that differ according to the age of the individual. Following routine HBV vaccination in adults and children, prevaccination and postvaccination serologic testing is not recommended because of the relatively low rate of HBV infection and the low cost of the vaccine. Postexposure prophylaxis for HBV with serologic testing is, however, necessary for all hospital personnel exposed to blood or body fluids. In addition, infants born from mothers not immunized to HBV or those who are infected with HBV also require comprehensive postexposure prophylaxis with serologic testing. Comprehensive immunization strategies with serologic testing must be implemented for all groups that have a high risk of HBV infection. Finally, vaccine information statements (VIS) must be carefully integrated in this comprehensive disease prevention strategy, which is designed to prevent the transmission of HBV in the United States.
-
Edlich Richard F., Olson Dana M., Olson Brianna M., Greene Jill Amanda, Gubler K. Dean, Winters Kathryne L., Poe Maia J., Britt L.D., Long William B., An Innovative Advance to Increase the Use of the Vaccine Information Statement, The Journal of Emergency Medicine, 33, 1, 2007. Crossref
-
Hershey Jody H., Schowalter Laurie, Bailey Stephanie B.C., Public health perspective on vaccine-preventable hepatitis: Integrating hepatitis A and B vaccines into public health settings, The American Journal of Medicine, 118, 10, 2005. Crossref
-
Ahmadinejad Zahra, Abdi Liae Zahra, Salehizadeh Saideh, Mansori Sedighe, Alijani Neda, Efficacy of Post-Exposure Prophylaxis in Infants Born to HBsAg Positive Mothers in Iran; Is It Authentic?, Iranian Journal of Pediatrics, In Press, In Press, 2016. Crossref
-
Lee Kyeong Hun, Shim Kyu Seok, Lim In Seok, Chae Soo Ahn, Yun Sin Weon, Lee Na Mi, Choi Young Bae, Yi Dae Yong, Changes in hepatitis B virus antibody titers over time among children: a single center study from 2012 to 2015 in an urban of South Korea, BMC Pediatrics, 17, 1, 2017. Crossref
-
Zhou Kali, Terrault Norah, Opioid use disorder and Chronic Hepatitis B, in The Opioid Epidemic and Infectious Diseases, 2021. Crossref
-
Zhang Conghui, Li Jie, Yang Lan, Xu Fengxia, She Huiyuan, Liu Xinghui, Huang Tao, Transcriptome Classification Reveals Molecular Subgroups in Patients with Hepatitis B Virus, Computational and Mathematical Methods in Medicine, 2021, 2021. Crossref
-
Angert Robert, Munjal Iona, Kalhan Tamara, Newborn Immunizations and Immune Prophylaxis, in Neonatology, 2020. Crossref